MarketPulse

AI-driven drug discovery

2 articles
BenzingaBenzinga··Globe Newswire

Pathos AI Acquires DeuterOncology to Commercialize Next-Gen MET Inhibitor

Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.
AZNTEMPhase 1 clinical trialoncology
BenzingaBenzinga··Prnewswire

Lunai Bioworks Lands First Defense Contract via AI Chemical Detection Platform

Lunai Bioworks subsidiary BioSymetrics secures first revenue-generating defense contract for AI-powered chemical threat detection platform; additional engagements under discussion.
LNAIdefense collaborationbiodefense